



**CHIEF MEDICAL OFFICER  
DEPARTMENT OF HEALTH  
MINISTRY FOR HEALTH, THE ELDERLY AND COMMUNITY CARE**

**DH CIRCULAR No.246/2011**  
DH 4953/2011

**7<sup>th</sup> November 2011**

**Attention All:** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Re: Combined Abacavir/Lamivudine 600mg/300mg preparation**

Abacavir/Lamivudine 600mg/300mg film coated tablets have been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for introduction onto the Government Formulary List.

The preparation is a fixed-dose combination of two nucleoside analogues. It is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age.

The recommended dose is one tablet once daily.

Consultant Infectious Diseases Physicians and Consultant Hospital Infection Control Physicians can prescribe Abacavir/Lamivudine 600mg/300mg for the treatment of HIV Type 1 infected adults and adolescents over 12 years, in combination with other antiretroviral medicinal products.

Abacavir/Lamivudine 600mg/300mg film coated tablets are protocol-regulated with protocol number 292 (attached).

Abacavir/Lamivudine 600mg/300mg film coated tablets have been procured through the Centralised Procurement and Supplies and are now available for use as per protocol.

Thank you

For your attention, please

Dr. Natasha Azzopardi Muscat  
Chief Medical Officer

“PALAZZO CASTELLANIA” 15, MERCHANTS STREET, VALLETTA, VLT 03

Tel. Nos. +00356 21224071/ 2299 2232

Fax no. +00356 2299 2663

e-mail: [dgss.mhec@gov.mt](mailto:dgss.mhec@gov.mt)

## **Combined Abacavir and Lamivudine (600mg/300mg) Preparation**

**Prescribed Criteria:** Consultant Infectious Disease  
Consultant Hospital Infection Control Physician

**Out-patient and In-patient use:**

1. HIV

HIV Type 1 infected adults and adolescents over 12 years, in combination with other antiretroviral medicinal products.

**Duration of Approval:**

3 years